<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol Sin</journal-id><journal-id journal-id-type="iso-abbrev">Virol Sin</journal-id><journal-title-group><journal-title>Virologica Sinica</journal-title></journal-title-group><issn pub-type="ppub">1674-0769</issn><issn pub-type="epub">1995-820X</issn><publisher><publisher-name>Springer Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7459973</article-id><article-id pub-id-type="publisher-id">283</article-id><article-id pub-id-type="doi">10.1007/s12250-020-00283-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Flu Universal Vaccines: New Tricks on an Old Virus</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9172-7824</contrib-id><name><surname>Du</surname><given-names>Ruikun</given-names></name><address><email>duzi857@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Qinghua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3938-0445</contrib-id><name><surname>Rong</surname><given-names>Lijun</given-names></name><address><email>lijun@uic.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.464402.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9459 9325</institution-id><institution>College of Pharmacy, </institution><institution>Shandong University of Traditional Chinese Medicine, </institution></institution-wrap>Jinan, 250355 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.464402.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9459 9325</institution-id><institution>Qingdao Academy of Chinese Medicinal Sciences, </institution><institution>Shandong University of Traditional Chinese Medicine, </institution></institution-wrap>Qingdao, 266122 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.464402.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9459 9325</institution-id><institution>Experimental Center, </institution><institution>Shandong University of Traditional Chinese Medicine, </institution></institution-wrap>Jinan, 250355 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.185648.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 0319</institution-id><institution>Department of Microbiology and Immunology, College of Medicine, </institution><institution>University of Illinois at Chicago, </institution></institution-wrap>Chicago, IL 60612 USA </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>9</month><year>2020</year></pub-date><fpage>1</fpage><lpage>12</lpage><history><date date-type="received"><day>6</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Wuhan Institute of Virology, CAS 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Conventional influenza vaccines are based on predicting the circulating viruses year by year, conferring limited effectiveness since the antigenicity of vaccine strains does not always match the circulating viruses. This necessitates development of universal influenza vaccines that provide broader and lasting protection against pan-influenza viruses. The discovery of the highly conserved immunogens (epitopes) of influenza viruses provides attractive targets for universal vaccine design. Here we review the current understanding with broadly protective immunogens (epitopes) and discuss several important considerations to achieve the goal of universal influenza vaccines.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Influenza virus</kwd><kwd>Universal vaccine</kwd><kwd>Conserved epitopes</kwd><kwd>Broadly protection</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">More than 100&#x000a0;years past the catastrophic 1918 Spanish influenza pandemic, influenza viruses remain a constant global health threat. Three types of influenza viruses infect humans: type A (influenza A virus, IAV), type B (IBV) and type C (ICV). Two IAV subtypes (H3N2 and H1N1pdm09) and two IBV lineages (Yamagata and Victoria) co-circulate annually, causing seasonal epidemics and up to 650,000 respiratory deaths globally, while ICV is detected less frequently and usually causes mild infections (Krammer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR58">2018</xref>; WHO <xref ref-type="bibr" rid="CR111">2018</xref>). In addition, antigenically novel IAVs generated by reassortment of the segmented genome can occasionally infect humans with high rates of morbidity and mortality, as well as potential pandemic risk (Krammer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR58">2018</xref>; WHO 2018).</p><p id="Par3">Vaccines provide cost-effective protection against influenza. Currently, seasonal influenza virus vaccines predominantly induce antibody responses against the hemagglutinin (HA), one of the two major surface glycoproteins of the virus (Krammer <xref ref-type="bibr" rid="CR54">2019</xref>). However, the majority of vaccine-induced antibodies are directed against the highly plastic head region of HA and are strain-specific (Caton <italic>et al.</italic>
<xref ref-type="bibr" rid="CR13">1982</xref>; Heaton <italic>et al.</italic>
<xref ref-type="bibr" rid="CR42">2013</xref>). Amino acid residues on the surface of this immunodominant head region vary substantially among different strains and change continuously (referred to as antigenic drift), leading to new circulating virus strains (Wang and Palese <xref ref-type="bibr" rid="CR102">2011</xref>). Therefore, current influenza vaccines have to be reformulated each year based on surveillance and prediction, which is cumbersome, and their effectiveness is highly variable depending on the accurate forecasts of the circulating strains in each year (de Jong <italic>et al.</italic>
<xref ref-type="bibr" rid="CR19">2000</xref>; Gerdil <xref ref-type="bibr" rid="CR35">2003</xref>). Moreover, the protection conferred by seasonal influenza vaccines does not cover emerging pandemic influenza virus strains.</p><p id="Par4">These limitations of current vaccines emphasize the need to develop novel &#x0201c;universal&#x0201d; or &#x0201c;broadly protective&#x0201d; influenza vaccines. An ideal universal vaccine should cover all influenza A and influenza B viruses independent of antigenic drift or HA/neuraminidase (NA) subtype. In contrast, a broadly protective vaccine would cover a large subset of influenza viruses, for example, all human seasonal influenza virus strains. These two types of vaccines are generally referred to as &#x0201c;universal vaccines&#x0201d; (Memoli <italic>et al.</italic>
<xref ref-type="bibr" rid="CR73">2019</xref>).</p><p id="Par5">Most universal vaccines in development aim at inducing broadly protective antibody responses, while some others focus on inducing T cell responses alternatively (Nachbagauer and Krammer <xref ref-type="bibr" rid="CR79">2017</xref>). In either case, the conserved immunogens of the virus need to be targeted, and the mechanism of protection mainly depends on the immunogens of choice (Nachbagauer and Krammer <xref ref-type="bibr" rid="CR79">2017</xref>; Asthagiri Arunkumar <italic>et al.</italic>
<xref ref-type="bibr" rid="CR4">2019</xref>). This review will discuss the conserved antigenic regions/epitopes of influenza viruses that can facilitate immunogen design and contribute to the development of universal influenza vaccines.</p></sec><sec id="Sec2"><title>Surface Proteins and Antibody Responses</title><p id="Par6">Induction of protective antibody responses against influenza viruses requires host recognition of the viral surface proteins, including HA, NA and matrix protein 2 (M2) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Thus the discovery of new broadly protective antibodies and related conserved epitopes can greatly accelerate design and implementation of universal vaccines (Deng and Wang <xref ref-type="bibr" rid="CR20">2018</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Influenza virus surface proteins. <bold>A</bold> A model of influenza viral particle with surface proteins. <bold>B</bold> Structures of the surface proteins. HA, Hemagglutinin; NA, neuraminidase; M2, matrix protein 2; M2e, extracellular region of M2.</p></caption><graphic xlink:href="12250_2020_283_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec3"><title>Hemagglutinin</title><p id="Par7">HA is assembled as homotrimers consisting of two domains, the membrane-distal globular head domain and the membrane-proximal helix-rich stalk domain (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B). Based on the antigenicity, HA can be divided into 18 subtypes, which fall into 2 groups, including group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18) and group 2 (H3, H4, H7, H10, H14, H15) (Du <italic>et al.</italic>
<xref ref-type="bibr" rid="CR25">2019</xref>). As mentioned above, HA head domain is the major target of the antibody response following vaccination with seasonal influenza vaccines, however its high plasticity makes it easy for the virus to escape immune pressure (Heaton <italic>et al.</italic>
<xref ref-type="bibr" rid="CR42">2013</xref>). Despite of this, monoclonal antibodies (mAbs) that cross-react between the head domains of different HA subtypes have been reported (Ekiert <italic>et al.</italic>
<xref ref-type="bibr" rid="CR29">2012</xref>; Krause <italic>et al.</italic>
<xref ref-type="bibr" rid="CR59">2012</xref>; Lee <italic>et al.</italic>
<xref ref-type="bibr" rid="CR61">2012</xref>; Boonsathorn <italic>et al.</italic>
<xref ref-type="bibr" rid="CR9">2014</xref>; Lee <italic>et al.</italic>
<xref ref-type="bibr" rid="CR62">2014</xref>). These cross-reactive head antibodies seem rare, but they are interesting since they suggest the existence of cross-reactive epitopes in the head domains.</p><p id="Par8">In contrast, HA stalk is the least variable region of HA, and great efforts have been focused on the development of universal influenza vaccines that depend on protective epitopes in this domain (Krammer and Palese <xref ref-type="bibr" rid="CR55">2015</xref>; Wu and Wilson <xref ref-type="bibr" rid="CR115">2018</xref>). Monoclonal antibodies against this domain can broadly neutralize different subtypes of group 1 (Okuno <italic>et al.</italic>
<xref ref-type="bibr" rid="CR81">1993</xref>; Ekiert <italic>et al.</italic>
<xref ref-type="bibr" rid="CR27">2009</xref>; Sui <italic>et al.</italic>
<xref ref-type="bibr" rid="CR93">2009</xref>) or group 2 viruses (Ekiert <italic>et al.</italic>
<xref ref-type="bibr" rid="CR28">2011</xref>) or even both (Corti <italic>et al.</italic>
<xref ref-type="bibr" rid="CR17">2011</xref>). Interestingly, although some stalk-antibodies show lower or even none neutralizing potency <italic>in vitro</italic>, they can render robust protection against challenges with divergent influenza viruses <italic>in vivo</italic> (Dreyfus <italic>et al.</italic>
<xref ref-type="bibr" rid="CR24">2012</xref>; DiLillo <italic>et al.</italic>
<xref ref-type="bibr" rid="CR22">2014</xref>; He <italic>et al.</italic>
<xref ref-type="bibr" rid="CR41">2015</xref>), most likely by Fc-mediated mechanisms like antibody dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Terajima <italic>et al.</italic>
<xref ref-type="bibr" rid="CR96">2011</xref>; Jegaskanda <italic>et al.</italic>
<xref ref-type="bibr" rid="CR46">2013a</xref>, <xref ref-type="bibr" rid="CR47">b</xref>; Miller <italic>et al.</italic>
<xref ref-type="bibr" rid="CR76">2013</xref>; DiLillo <italic>et al.</italic>
<xref ref-type="bibr" rid="CR22">2014</xref>; Florek <italic>et al.</italic>
<xref ref-type="bibr" rid="CR34">2014</xref>; Jegaskanda <italic>et al.</italic>
<xref ref-type="bibr" rid="CR48">2014</xref>).</p><p id="Par9">Glycosylation and conformational mobility (shape-shifting) of surface glycoproteins can help viruses to mask sensitive epitopes and evade the immune system. Interestingly, two latest studies revealed that glycan repositioning within either head or stem domains of HA can facilitate the elicitation of protective cross-reactive antibody responses. Huang <italic>et al.</italic> reported that removing glycosylation at residue 144 and deletion of lysine at position 147 can synergize to elicit broadly-reactive H1N1 influenza antibodies (Huang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR44">2019</xref>). A study by Boyoglu-Barnum <italic>et al.</italic> showed that introduction of the group 2 glycan at Asn38HA1 to a group 1 stem-nanoparticle can broaden antibody responses to cross-react with group 2 HAs (Boyoglu-Barnum <italic>et al.</italic>
<xref ref-type="bibr" rid="CR10">2020</xref>). Although the precise sites that are vulnerable by glycan repositioning are not identified yet, they may provide novel target epitopes to achieve universal protection.</p><p id="Par10">More recently, a novel conserved epitope at the HA head domain trimer interface was reported (Bajic <italic>et al.</italic>
<xref ref-type="bibr" rid="CR5">2019</xref>; Bangaru <italic>et al.</italic>
<xref ref-type="bibr" rid="CR6">2019</xref>; Watanabe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR106">2019</xref>). Primarily, the epitope is occluded at the contact surface between HA head domains, while the reversible HA &#x0201c;breathing&#x0201d; conformational dynamics can cause exposure of the interface. Antibodies targeting this cryptic epitope were shown to be protective against broad-spectrum subtypes of IAVs, suggesting the HA head interface is a new potential immunogen component for influenza universal vaccine design (Bajic <italic>et al.</italic>
<xref ref-type="bibr" rid="CR5">2019</xref>; Bangaru <italic>et al.</italic>
<xref ref-type="bibr" rid="CR6">2019</xref>; Watanabe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR106">2019</xref>; Wu and Gao <xref ref-type="bibr" rid="CR114">2019</xref>).</p></sec><sec id="Sec4"><title>Neuraminidase</title><p id="Par11">NA is the second most abundant glycoprotein on the surface of influenza A and B viruses, and plays an essential role during virus replication by facilitating release of progeny virions (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B) (Du <italic>et al.</italic>
<xref ref-type="bibr" rid="CR25">2019</xref>). It is well known that NA antibodies can protect against infection of influenza viruses (Schulman <italic>et al.</italic>
<xref ref-type="bibr" rid="CR86">1968</xref>; Murphy <italic>et al.</italic>
<xref ref-type="bibr" rid="CR78">1972</xref>; Monto and Kendal <xref ref-type="bibr" rid="CR77">1973</xref>; Doyle <italic>et al.</italic>
<xref ref-type="bibr" rid="CR23">2013</xref>; Wan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR101">2013</xref>; Wilson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR109">2016</xref>; Wohlbold <italic>et al.</italic>
<xref ref-type="bibr" rid="CR110">2017</xref>), by preventing virus budding and egress from infected cells, as well as ADCC and CDC (Wan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR101">2013</xref>; Krammer and Palese <xref ref-type="bibr" rid="CR55">2015</xref>; Wohlbold <italic>et al.</italic>
<xref ref-type="bibr" rid="CR110">2017</xref>). NA consists of 11 subtypes (N1 to N11), and a series of &#x0201c;broadly&#x0201d; cross-reactive mAbs of NA have been isolated (Wan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR101">2013</xref>; Wilson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR109">2016</xref>; Wohlbold <italic>et al.</italic>
<xref ref-type="bibr" rid="CR110">2017</xref>; Chen <italic>et al.</italic>
<xref ref-type="bibr" rid="CR14">2018</xref>). Of note, most of these cross-reactive NA mAbs are limited to recognize heterologous virus strains of the same NA subtype, suggesting existence of conserved subtype-specific NA epitopes (Wan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR101">2013</xref>; Wilson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR109">2016</xref>; Wohlbold <italic>et al.</italic>
<xref ref-type="bibr" rid="CR110">2017</xref>; Chen <italic>et al.</italic>
<xref ref-type="bibr" rid="CR14">2018</xref>).</p><p id="Par12">Interestingly, Doyle <italic>et al.</italic> reported a unique universally conserved sequence (amino acids 222&#x02013;230, located in the vicinity of enzymatic active site) amongst all&#x000a0;IAV NA subtypes, and a mAb&#x000a0;targeting this specific epitope was demonstrated to inhibit all&#x000a0;NA subtypes&#x000a0;and protect mice from lethal doses of mouse-adapted H1N1 and H3N2 (Doyle <italic>et al.</italic>
<xref ref-type="bibr" rid="CR23">2013</xref>). More recently, Stadlbauer <italic>et al.</italic> identified three broadly-protective mAbs targeting the NA active site that is highly conserved among all NA subtypes (Stadlbauer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR91">2019</xref>). These conserved NA epitopes, either subtype specific or universal, may be attractive immunological target for universal influenza vaccine design.</p></sec><sec id="Sec5"><title>Matrix Protein 2</title><p id="Par13">M2 of IAV (AM2) is a type III integral membrane protein, consisting of an N-terminal extracellular region (M2e), transmembrane region, and C-terminal cytoplasmic tail region (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B) (Tobler <italic>et al.</italic>
<xref ref-type="bibr" rid="CR97">1999</xref>). The M2e is a 24-residue peptide and is highly conserved among different IAV subtypes (Deng <italic>et al.</italic>
<xref ref-type="bibr" rid="CR21">2015</xref>). Although the natural M2e has low immunogenicity and abundance, a M2e-specific and protective monoclonal antibody 14C2 has been isolated early (Zebedee and Lamb <xref ref-type="bibr" rid="CR118">1989</xref>; Treanor <italic>et al.</italic>
<xref ref-type="bibr" rid="CR98">1990</xref>). Therefore this region has since been extensively evaluated as a promising immunogen for universal influenza vaccines (Farahmand <italic>et al.</italic>
<xref ref-type="bibr" rid="CR33">2019</xref>; Yao <italic>et al.</italic>
<xref ref-type="bibr" rid="CR116">2019</xref>).</p><p id="Par14">BM2 of IBV is a functional homolog of AM2 but shares little sequence identity (Wanitchang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR105">2016</xref>; Mandala <italic>et al.</italic>
<xref ref-type="bibr" rid="CR70">2019</xref>), and most mAbs targeting M2e are IAV-wide. Despite a mAb AS2 that recognizes the conservative N-terminus of M2 (amino acids 2&#x02013;10) has been identified to possess neutralizing activity against both IAV and IBV <italic>in vitro</italic> (Liu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR66">2003</xref>), no evidence showed that immunity with current universal influenza vaccine candidates based on M2e of IAV can suppress IBV replication (Mezhenskaya <italic>et al.</italic>
<xref ref-type="bibr" rid="CR75">2019</xref>).</p></sec></sec><sec id="Sec6"><title>Internal Proteins and T-cell Responses</title><p id="Par15">CD8<sup>+</sup> T cells can detect and kill virus-infected cells by recognizing viral protein-derived peptides (epitopes) presented by major histocompatibility complex class I (MHC-I) on the cell surface (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). While CD8<sup>+</sup> T cell-based immunity does not prevent infection, it can facilitate viral clearance and reduce the severity of disease (McMichael <italic>et al.</italic>
<xref ref-type="bibr" rid="CR72">1983</xref>; Sridhar <italic>et al.</italic>
<xref ref-type="bibr" rid="CR90">2013</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>T-cell response and influenza viral internal proteins. <bold>A</bold> CD8<sup>+</sup> T cell response. Virus-derived peptide antigens presented by major histocompatibility complex-I (MHC-1) at surface of virus infected cells can be recognized by CD8<sup>+</sup> T cells through specific T cell receptors (TCRs), resulting in lysis of target cells. <bold>B</bold> A model of influenza viral particle with internal proteins. M1, Matrix protein 1; NP, nucleoprotein; PB1, polymerase basic-1. *, CD8<sup>+</sup> T cell targets from IBV HA and NS (nonstructural protein 1) proteins also have been reported.</p></caption><graphic xlink:href="12250_2020_283_Fig2_HTML" id="MO2"/></fig></p><p id="Par16">The current inactivated influenza vaccine formulation does not boost T cell response (Koutsakos <italic>et al.</italic>
<xref ref-type="bibr" rid="CR52">2018</xref>). Nevertheless cytotoxic CD8<sup>+</sup> T cells specific to the conserved viral epitopes have been evidenced to provide cross-protection across IAV, IBV and ICV (McMichael <italic>et al.</italic>
<xref ref-type="bibr" rid="CR72">1983</xref>; Greenbaum <italic>et al.</italic>
<xref ref-type="bibr" rid="CR38">2009</xref>; Gras <italic>et al.</italic>
<xref ref-type="bibr" rid="CR36">2010</xref>; Sridhar <italic>et al.</italic>
<xref ref-type="bibr" rid="CR90">2013</xref>; Quinones-Parra <italic>et al.</italic>
<xref ref-type="bibr" rid="CR84">2014</xref>; Hayward <italic>et al.</italic>
<xref ref-type="bibr" rid="CR40">2015</xref>; Wang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR103">2015</xref>, <xref ref-type="bibr" rid="CR104">2018</xref>; Koutsakos <italic>et al.</italic>
<xref ref-type="bibr" rid="CR53">2019</xref>). Moreover, pre-existing T cell responses have been demonstrated to correlate with protection from influenza disease in humans by epidemiological studies (Epstein <xref ref-type="bibr" rid="CR31">2006</xref>; Hayward <italic>et al.</italic>
<xref ref-type="bibr" rid="CR40">2015</xref>). The antigenic origin of these broadly cross-reactive epitopes is therefore of great interest in the development of CD8<sup>+</sup> T cell-based universal influenza vaccines. It is believed that CD8<sup>+</sup> T cell cross-reactivity is provided by the peptides derived from internal influenza proteins, mainly but not limited to nucleoprotein (NP) and matrix protein 1 (M1) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B) (Koutsakos <italic>et al.</italic>
<xref ref-type="bibr" rid="CR53">2019</xref>).</p><p id="Par17">In contrast to HA and NA, the internal influenza virus proteins are relatively well conserved and display limited antigenic diversity (Bui <italic>et al.</italic>
<xref ref-type="bibr" rid="CR12">2007</xref>). A number of vaccine candidates have been developed to induce T cell responses, by intracellularly expressing NP and M1 using replication deficient viral vectors like Chimpanzee Adenovirus Oxford 1 (ChAdOx1) or Modified Vaccinia Ankara (MVA) (Berthoud <italic>et al.</italic>
<xref ref-type="bibr" rid="CR8">2011</xref>; Lillie <italic>et al.</italic>
<xref ref-type="bibr" rid="CR64">2012</xref>; Lambe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR60">2013</xref>; Antrobus <italic>et al.</italic>
<xref ref-type="bibr" rid="CR2">2014a</xref>, <xref ref-type="bibr" rid="CR3">b</xref>).</p><p id="Par18">Interestingly, a recent study identified a universal PB1 epitope (PB1<sub>413</sub>), which is derived from a core motif (residues 406&#x02013;422 of IAV-PB1 protein) present in the viral RNA-dependent polymerases (Koutsakos <italic>et al.</italic>
<xref ref-type="bibr" rid="CR53">2019</xref>). PB1 is the most conserved protein across IAV and IBV, with about 60% amino acid identity. Vaccinating against the T cell epitope PB1<sub>413</sub> might provide universal protection in humans. Besides, CD8<sup>+</sup> T cell targets from IBV HA and NS1 proteins also have been identified and shown IBV-specific protection in mice, suggesting them as ideal targets for IBV-wide influenza vaccines (Koutsakos <italic>et al.</italic>
<xref ref-type="bibr" rid="CR53">2019</xref>).</p><p id="Par19">CD4<sup>+</sup> T cell responses to influenza virus and their role for host protection against influenza infection have received increasing attention (Wilkinson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR108">2012</xref>). It has been well demonstrated that CD4<sup>+</sup> memory T cells can help in directing a faster antibody response via cytokine secretion in response to mutated or immunologically novel viral antigens, leading to limited virus shedding and disease severity, possibly due to the direct lysis of infected epithelial cells (Poon <italic>et al.</italic>
<xref ref-type="bibr" rid="CR83">2009</xref>; Wilkinson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR108">2012</xref>; Valkenburg <italic>et al.</italic>
<xref ref-type="bibr" rid="CR100">2018</xref>). A vaccine that can induce CD8<sup>+</sup> or CD4<sup>+</sup> T responses against highly conserved regions of the influenza proteins may overcome the limitations of current season influenza vaccines (Sheikh <italic>et al.</italic>
<xref ref-type="bibr" rid="CR89">2016</xref>). More importantly, universal T cell-inducing vaccines in combination with universal antibodies can confer increased protection against influenza (Asthagiri Arunkumar <italic>et al.</italic>
<xref ref-type="bibr" rid="CR4">2019</xref>).</p></sec><sec id="Sec7"><title>Obstacles and Strategies</title><p id="Par20">In theory, a universal influenza vaccine would work well if it contains a conserved epitope that remains the same from year to year and does not vary between strains. However, no such viral epitope capable of stimulating an immune response that stops most influenza viruses afflicting humans has been reported yet (Cohen <xref ref-type="bibr" rid="CR15">2018</xref>). Certainly there are main obstacles on the way to developing universal influenza vaccines, but different strategies can be used to overcome them.</p><sec id="Sec8"><title>Low Immunogenicity and Immunofocusing</title><p id="Par21">Specific induction of broadly neutralizing antibodies can be achieved by targeting B cell recognition to conserved epitopes. However, the low immunogenicity of the conserved HA stalk and M2e makes antibody responses targeting these antigens constitute only a small fraction of the total anti-virus antibodies in nature infections (Sui <italic>et al.</italic>
<xref ref-type="bibr" rid="CR94">2011</xref>). Various immunofocusing approaches have been therefore developed to overcome this problem.</p><p id="Par22">The M2e is small in size and has low abundance in its native state, but its immunogenicity can be improved using tandem repeats and fusing them to highly immunogenic carriers (Neirynck <italic>et al.</italic>
<xref ref-type="bibr" rid="CR80">1999</xref>; De Filette <italic>et al.</italic>
<xref ref-type="bibr" rid="CR18">2008</xref>; Eliasson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR30">2008</xref>; Turley <italic>et al.</italic>
<xref ref-type="bibr" rid="CR99">2011</xref>; Kim <italic>et al.</italic>
<xref ref-type="bibr" rid="CR51">2013</xref>). Strategies directing the antibody response to HA stalk were also evaluated, such as shielding of the HA head epitopes by hyperglycosylation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A) (Lin <italic>et al.</italic>
<xref ref-type="bibr" rid="CR65">2012</xref>; Eggink <italic>et al.</italic>
<xref ref-type="bibr" rid="CR26">2014</xref>), and constructing headless mini-HA as protective immunogen by removing the head domain completely (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B) (Steel <italic>et al.</italic>
<xref ref-type="bibr" rid="CR92">2010</xref>). Notably, the latter strategy requires maintaining the conformation of the stalk domain in absence of the head domain, which is challenging. Nevertheless promise progress has been made to achieve the stable native structure of trimeric HA stalk, either in soluble form or presented on nanoparticles (Lu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR68">2014</xref>; Mallajosyula <italic>et al.</italic>
<xref ref-type="bibr" rid="CR69">2014</xref>; Impagliazzo <italic>et al.</italic>
<xref ref-type="bibr" rid="CR45">2015</xref>; Yassine <italic>et al.</italic>
<xref ref-type="bibr" rid="CR117">2015</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Immunofocusing approaches for a universal flu vaccine. <bold>A</bold> Head masking. The &#x0201c;Head&#x0201d; region of trimeric HA was hyperglycosylated, leaving only the HA stalk immunogenic. <bold>B</bold> Mini-HA. The &#x0201c;Head&#x0201d; region of trimeric HA was removed completely, while the conformation of the stalk domain maintains well. <bold>C</bold> Schematic of the PMD strategy. First, the epitope of interest is protected by binding of specific mAb. Then the surface of the protein&#x000b7;mAb complex is modified and rendered nonimmunogenic (shown as grey). By removal of the mAb, the epitope is deprotected and exposed as PMD antigen.</p></caption><graphic xlink:href="12250_2020_283_Fig3_HTML" id="MO3"/></fig></p><p id="Par23">More recently, Weidenbacher and Kim developed a novel method, called protect, modify, deprotect (PMD), for creating immunogens aimed to elicit antibodies targeting a specific epitope (Weidenbacher and Kim <xref ref-type="bibr" rid="CR107">2019</xref>). A monoclonal antibody that recognizes the specific epitope is used to protect the target epitope on the protein, followed by modifications of the remaining exposed surfaces of the protein to render them nonimmunogenic. After removal of the monoclonal antibody, the epitope is deprotected and the resultant protein is modified at the surface other than the target epitope (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C). The increasing numbers of broadly-neutralizing mAbs and corresponding conserved epitopes may provide attractive targets for the application of PMD in universal influenza vaccine design.</p></sec><sec id="Sec9"><title>Immunodominance and Immunosubversion</title><p id="Par24">The success of mini-HA in inducing robust stalk-specific antibodies strongly implies that the HA stalk is not intrinsically poorly immunogenic, but is the victim of immunodominance, where the immune system tends to respond to complex antigens in a reproducibly hierarchical manner, that is, higher-ranking antigens sometimes suppress responses to lower ranking antigens (Angeletti and Yewdell <xref ref-type="bibr" rid="CR1">2018</xref>). In the case of IAV HA, there is clear head immunodomination over stalk.</p><p id="Par25">However, immunodominance can be subverted by various strategies. For example, an &#x0201c;antigen imprinting&#x0201d; strategy was inspired by the phenomenon that natural infection and vaccination with pandemic H1N1 in 2009 preferentially boosted broadly binding antibodies in humans including antibodies targeting the stalk domain (Wrammert <italic>et al.</italic>
<xref ref-type="bibr" rid="CR113">2011</xref>; Li <italic>et al.</italic>
<xref ref-type="bibr" rid="CR63">2012</xref>; Pica <italic>et al.</italic>
<xref ref-type="bibr" rid="CR82">2012</xref>). Generally, immune response against newly emerging strains of influenza virus would be affected by immune memory acquired by past influenza exposure; memory B cells that are cross-reactive with newly emerging strains is activated, while induction of strain-specific antibodies is prevented (Henry <italic>et al.</italic>
<xref ref-type="bibr" rid="CR43">2018</xref>). In this strategy, chimeric HAs that share the same stalk domain but express different head domains were constructed and used for vaccination sequentially, allowing repeated exposure of the same stalk in the context of an irrelevant globular head domain (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A) (Hai <italic>et al.</italic>
<xref ref-type="bibr" rid="CR39">2012</xref>; Krammer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR57">2013</xref>; Margine <italic>et al.</italic>
<xref ref-type="bibr" rid="CR71">2013</xref>; Ermler <italic>et al.</italic>
<xref ref-type="bibr" rid="CR32">2017</xref>). The first immunization with a chimeric HA construct leads to a primary response against the globular head domain and, though much less efficiently, against the stalk domain. Upon subsequent booster vaccinations, a recall response against the stalk is anticipated, but immune response against the immunodominant head domain is restricted.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>immunosubversion strategies for a universal flu vaccine. <bold>A</bold> Chimeric hemagglutinin (cHA) constructs and vaccination strategy. The cHAs consist of a conserved stalk domain in combination with &#x0201c;heads&#x0201d; from different avian influenza virus HA subtypes. Vaccination with the first cHA leads to primary antibody responses mainly targeting the immunodominant head domain and low-level priming against the stalk domain. Upon boosting with a second cHA that has the same stalk domain but a completely different head domain, the immune system induces a primary response against the novel head domain and a strong memory response against the stalk domain. <bold>B</bold> Mosaic hemagglutinin (mHA) constructs and vaccination strategy. Only the variable immunodominant antigenic sites in mHAs are replaced with antigenic site equivalents from different influenza virus HA subtypes, and the resulting mHA displays conserved epitopes in both the stalk and head domains. Vaccination with the first mHA likely induces a strong primary response against the grafted antigenic sites and low-level priming for conserved epitopes in the stalk and head domains. Revaccination with a second mHA with antigenic sites that have been grafted from a different subtype might result in a primary response against the antigenic sites and a strong recall response against conserved epitopes in both the head and stalk domains. <bold>C</bold> Model of immunosubversion approach with mosaic antigen array. Colored and black simbols indicates strain specific and conserved antigens respectivley. B cells possessing BCRs specific to multiple antigenic variants are colored accordingly. The avidity advantage of the mosaic antigen to cross-reactive B cells over mono-specific B cells is anticipated, promoting proliferation of cross-reactive B cells.</p></caption><graphic xlink:href="12250_2020_283_Fig4_HTML" id="MO4"/></fig></p><p id="Par26">To further include head-specific cross-reactive epitopes into consideration for universal vaccine design, Krammer and Palese proposed a novel concept of mosaic HAs, which were constructed by replacing the immunodominant antigenic sites in the head with sequences from exotic, avian HA subtypes, instead of changing the whole head domain (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B) (Broecker <italic>et al.</italic>
<xref ref-type="bibr" rid="CR11">2018</xref>; Liu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR67">2018</xref>; Krammer and Palese <xref ref-type="bibr" rid="CR56">2019</xref>). Such a vaccination regimen can induce antibodies targeting both conserved HA stalk and conserved epitopes in the head&#x000a0;domain, possessing improved potential as universal vaccines (Sun <italic>et al.</italic>
<xref ref-type="bibr" rid="CR95">2019</xref>).</p><p id="Par27">Recently, Kanekiyo <italic>et al.</italic> developed a novel immunosubversion strategy by enhancing the avidity of immunogens to cross-reactive B cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C) (Kanekiyo <italic>et al.</italic>
<xref ref-type="bibr" rid="CR50">2019</xref>). Heterotypic influenza hemagglutinin antigens were co-localized on a single nanoparticle, generating a mosaic array. After vaccination, the avidity advantage of conserved epitopes to B cells can be achieved over strain-specific B cells, i.e., the B cell responses can adaptively target conserved antigenic surfaces, promoting cross-reactive antibody secretion. This heterotypic mosaic nanoparticle immunogen provides a new tool to combat viral genetic plasticity and antigenic variation.</p><p id="Par28">Of note, a latest study using an African green monkey IAV model revealed that although mismatched prime-boost generated a pool of stem-specific memory B cells, head-specific B cells and serum Abs still substantially dominated the immune response (Jegaskanda <italic>et al.</italic>
<xref ref-type="bibr" rid="CR49">2019</xref>). Moreover, it&#x02019;s theoretically proven that, at least in prime-boost model of mice, memory B cell (MBC) clones seldom reenter secondary germinal centers upon boosting (Mesin <italic>et al.</italic>
<xref ref-type="bibr" rid="CR74">2020</xref>). The rearrangement of MBC clones were therefore blocked, and the diversity and specificity were limited, restricting the breadth and effectiveness of the ensuing antibody response (Mesin <italic>et al.</italic>
<xref ref-type="bibr" rid="CR74">2020</xref>). If this clonality bottleneck is also the case of humans, our ability to elicit antibodies to non-immunodominant epitopes may be further improved once the bottleneck is solved in future.</p></sec><sec id="Sec10"><title>Original Antigenic Sin Versus Additive Approach</title><p id="Par29">&#x0201c;Original Antigenic Sin (OAS)&#x0201d; refers to the phenomenon that the antibody response to the first influenza virus variant one encounters dominates the anti-influenza virus antibody response lifelong (reviewed in (Henry <italic>et al.</italic>
<xref ref-type="bibr" rid="CR43">2018</xref>)). To date, the knowledge of how past influenza exposure shapes the response to subsequent antigenically distinct influenza strains remains obscure. Although &#x0201c;antigen imprinting&#x0201d; strategy has shown positive impact in the context of the development of a &#x0201c;stalk-based&#x0201d; universal influenza virus vaccine, the complex immune response underlying OAS more or less stymies the development of universal influenza vaccines (Cohen <xref ref-type="bibr" rid="CR15">2018</xref>).</p><p id="Par30">Additive approach by either serial vaccination or combined vaccination with multiple antigenic types has been successfully employed to produce pneumococcal conjugate vaccines (13 different antigens) and human papillomavirus vaccines (up to nine different antigens), which can elicit accumulated responses with non-overlapping specificities. For influenza vaccines, admixture of multivalent influenza vaccines may result in antigenic competition and eventually lead to loss of efficacy for one or more components (Kanekiyo <italic>et al.</italic>
<xref ref-type="bibr" rid="CR50">2019</xref>). Moreover, broad immunity has not been achieved by serial immunization with conventional flu vaccines (Belongia <italic>et al.</italic>
<xref ref-type="bibr" rid="CR7">2017</xref>).</p><p id="Par31">It is argued by Worobey <italic>et al.</italic> that the propensity of initial influenza virus exposure to establish a lifelong immunological imprint also presents a remarkable opportunity: immunization of infants prior to their initial, natural virus exposure with multiple versions of common human subtypes simultaneously may promise extended immunological imprinting across all currently circulating strains and against potential pandemic strains of IAV. This approach might be a possible step toward a universal vaccine (Cohen <xref ref-type="bibr" rid="CR15">2018</xref>; Worobey <italic>et al.</italic>
<xref ref-type="bibr" rid="CR112">2020</xref>).</p></sec></sec><sec id="Sec11"><title>Future Prospects</title><p id="Par32">Decades have been spent to concoct universal influenza vaccines, and some solid progress has been achieved. Currently, several vaccine candidates are in early human clinical trials, with each vaccine candidate exploiting conserved regions of the virus to maximize breadth [reviewed in (Nachbagauer and Krammer, <xref ref-type="bibr" rid="CR79">2017</xref>)]. Although some vaccine candidates such as those featured HA stalk have underwhelmed vaccine developers due to their poor effectiveness (Cohen <xref ref-type="bibr" rid="CR15">2018</xref>), increasing numbers of new effective broad-protective immunogens (epitopes) have been discovered, providing attractive targets that should be explored in the development of novel universal influenza vaccines (Bajic <italic>et al.</italic>
<xref ref-type="bibr" rid="CR5">2019</xref>; Bangaru <italic>et al.</italic>
<xref ref-type="bibr" rid="CR6">2019</xref>; Stadlbauer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR91">2019</xref>; Watanabe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR106">2019</xref>).</p><p id="Par33">Of particularly note, some of the novel conserved epitopes are discontinuous (Stadlbauer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR91">2019</xref>) or even occluded in their native state (Bajic <italic>et al.</italic>
<xref ref-type="bibr" rid="CR5">2019</xref>; Bangaru <italic>et al.</italic>
<xref ref-type="bibr" rid="CR6">2019</xref>; Watanabe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR106">2019</xref>). How one can obtain and immunize against these epitopes remains a big issue. The advantage of synthetic epitope mimetics and de novo protein design may facilitate immunogens design for universal influenza vaccines in the future (Zerbe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR119">2017</xref>; Grayson and Anderson <xref ref-type="bibr" rid="CR37">2018</xref>).</p><sec id="Sec12"><title>Synthetic Epitope Mimetics</title><p id="Par34">The huge growth in high-resolution 3D structures of proteins promotes the emergence of a novel paradigm in the study of biomolecular recognition, the design and synthesis of protein epitope mimetics. Based on the natural structure of interested epitope, the mimetics (synthetic peptides) can be designed and synthesized, with diverse chemistries and cross-links (e.g., helix-stabilizing staples) harnessed to achieve desired folding (Zerbe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR119">2017</xref>).</p><p id="Par35">Recent technological advances have suggested the promising potential of synthetic peptides as antigens to generate focused immune responses. By coupling a mimetic of the V3 loop from HIV-1 GP120 to synthetic virus-like nanoparticles, Riedel <italic>et al.</italic> successfully designed a candidate HIV-1 vaccine which can elicit antibodies in rabbits that recognized recombinant gp120 (Riedel <italic>et al.</italic>
<xref ref-type="bibr" rid="CR85">2011</xref>). Moreover, both folded B- and linear T- epitopes can be displayed on the engineered nanoparticles, inducing antibody response and T-cell response respectively (Zerbe <italic>et al.</italic>
<xref ref-type="bibr" rid="CR119">2017</xref>).</p></sec><sec id="Sec13"><title><italic>De Novo</italic> Immunogen Design</title><p id="Par36">The computational design of new proteins sparks hopes in the field of rational vaccinology, particularly to elicit targeted neutralizing antibody responses (Correia <italic>et al.</italic>
<xref ref-type="bibr" rid="CR16">2014</xref>; Sesterhenn <italic>et al.</italic>
<xref ref-type="bibr" rid="CR87">2019</xref>). While most de novo proteins designed so far are either functionless or present functions that are encoded by regular, continuous secondary structures. Interestingly, a great progress has been made recently by Sesterhenn <italic>et al.</italic>, who developed a novel computational design strategy to build de novo proteins presenting complex structural motifs (Sesterhenn <italic>et al.</italic>
<xref ref-type="bibr" rid="CR88">2020</xref>). By using this strategy, the authors further engineered epitope-focused immunogens mimicking irregular and discontinuous RSV neutralization epitopes. And excitingly, the de novo&#x02013;designed immunogens can induce robust neutralizing responses against the respiratory syncytial virus in both mice and nonhuman primates (Sesterhenn <italic>et al.</italic>
<xref ref-type="bibr" rid="CR88">2020</xref>).</p></sec></sec><sec id="Sec14"><title>Conclusions</title><p id="Par37">The ever-changing influenza surface proteins, HA and NA, arouse the desire of a universal flu vaccine. By offering life-long protection against all influenza strains, an universal vaccine can greatly reduce the need for yearly vaccine reformulations and vaccination. So far, many universal influenza vaccine candidates that are in clinical trials focus on targeting conserved epitopes of influenza, including either surface proteins or highly conserved internal proteins. Moreover, the new identified highly conserved epitopes and advanced techniques will lead to the fast development of next-generation universal flu vaccines.</p></sec></body><back><ack><title>Acknowledgements</title><p>This work was supported by The Drug Innovation Major Project (Grant No. 2018ZX09711001), the Key Research and Development Projects of Science and Technology Department of Shandong Province (Grant No. 2017CXGC1309) and Shandong Provincial Natural Science Foundation of China (Grant No. ZR2019MH078; ZR2017MH086).</p></ack><notes><title>Compliance with Ethical Standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par38">The authors declare that they have no conflict of interest.</p></notes><notes id="FPar2"><title>Animal and Human Rights Statement</title><p id="Par39">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeletti</surname><given-names>D</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name></person-group><article-title>Is it possible to develop a &#x0201c;universal&#x0201d; influenza virus vaccine? Outflanking antibody immunodominance on the road to universal influenza vaccination</article-title><source>Cold Spring Harb Perspect Biol</source><year>2018</year><volume>10</volume><fpage>a028852</fpage><?supplied-pmid 28663210?><pub-id pub-id-type="pmid">28663210</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antrobus</surname><given-names>RD</given-names></name><name><surname>Berthoud</surname><given-names>TK</given-names></name><name><surname>Mullarkey</surname><given-names>CE</given-names></name><name><surname>Hoschler</surname><given-names>K</given-names></name><name><surname>Coughlan</surname><given-names>L</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Coadministration of seasonal influenza vaccine and MVA-NP&#x02009;+&#x02009;M1 simultaneously achieves potent humoral and cell-mediated responses</article-title><source>Mol Ther</source><year>2014</year><volume>22</volume><fpage>233</fpage><lpage>238</lpage><?supplied-pmid 23831594?><pub-id pub-id-type="pmid">23831594</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antrobus</surname><given-names>RD</given-names></name><name><surname>Coughlan</surname><given-names>L</given-names></name><name><surname>Berthoud</surname><given-names>TK</given-names></name><name><surname>Dicks</surname><given-names>MD</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens</article-title><source>Mol Ther</source><year>2014</year><volume>22</volume><fpage>668</fpage><lpage>674</lpage><?supplied-pmid 24374965?><pub-id pub-id-type="pmid">24374965</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asthagiri Arunkumar</surname><given-names>G</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Pavot</surname><given-names>V</given-names></name><name><surname>Aramouni</surname><given-names>M</given-names></name><name><surname>Ioannou</surname><given-names>A</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>5567</fpage><lpage>5577</lpage><?supplied-pmid 31399277?><pub-id pub-id-type="pmid">31399277</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajic</surname><given-names>G</given-names></name><name><surname>Maron</surname><given-names>MJ</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>McCarthy</surname><given-names>KR</given-names></name><name><surname>McGee</surname><given-names>CE</given-names></name><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Kuraoka</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name></person-group><article-title>Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope</article-title><source>Cell Host Microb</source><year>2019</year><volume>25</volume><issue>827&#x02013;835</issue><fpage>e826</fpage></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangaru</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Vanderven</surname><given-names>HA</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><name><surname>Bombardi</surname><given-names>R</given-names></name><name><surname>Finn</surname><given-names>JA</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Gilchuk</surname><given-names>P</given-names></name><name><surname>Gilchuk</surname><given-names>I</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface</article-title><source>Cell</source><year>2019</year><volume>177</volume><issue>1136&#x02013;1152</issue><fpage>e1118</fpage></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belongia</surname><given-names>EA</given-names></name><name><surname>Skowronski</surname><given-names>DM</given-names></name><name><surname>McLean</surname><given-names>HQ</given-names></name><name><surname>Chambers</surname><given-names>C</given-names></name><name><surname>Sundaram</surname><given-names>ME</given-names></name><name><surname>De Serres</surname><given-names>G</given-names></name></person-group><article-title>Repeated annual influenza vaccination and vaccine effectiveness: review of evidence</article-title><source>Expert Rev Vaccin</source><year>2017</year><volume>16</volume><fpage>1</fpage><lpage>14</lpage></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berthoud</surname><given-names>TK</given-names></name><name><surname>Hamill</surname><given-names>M</given-names></name><name><surname>Lillie</surname><given-names>PJ</given-names></name><name><surname>Hwenda</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>KA</given-names></name><name><surname>Ewer</surname><given-names>KJ</given-names></name><name><surname>Milicic</surname><given-names>A</given-names></name><name><surname>Poyntz</surname><given-names>HC</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Fletcher</surname><given-names>HA</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Potent CD8&#x02009;+&#x02009;T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP&#x02009;+&#x02009;M1</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>1</fpage><lpage>7</lpage><?supplied-pmid 21148512?><pub-id pub-id-type="pmid">21148512</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonsathorn</surname><given-names>N</given-names></name><name><surname>Panthong</surname><given-names>S</given-names></name><name><surname>Koksunan</surname><given-names>S</given-names></name><name><surname>Chittaganpitch</surname><given-names>M</given-names></name><name><surname>Phuygun</surname><given-names>S</given-names></name><name><surname>Waicharoen</surname><given-names>S</given-names></name><name><surname>Prachasupap</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Kubota-Koketsu</surname><given-names>R</given-names></name><name><surname>Yasugi</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Kurosu</surname><given-names>T</given-names></name><name><surname>Sawanpanyalert</surname><given-names>P</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name></person-group><article-title>A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses</article-title><source>Biochem Biophys Res Commun</source><year>2014</year><volume>452</volume><fpage>865</fpage><lpage>870</lpage><?supplied-pmid 25204499?><pub-id pub-id-type="pmid">25204499</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyoglu-Barnum</surname><given-names>S</given-names></name><name><surname>Hutchinson</surname><given-names>GB</given-names></name><name><surname>Boyington</surname><given-names>JC</given-names></name><name><surname>Moin</surname><given-names>SM</given-names></name><name><surname>Gillespie</surname><given-names>RA</given-names></name><name><surname>Tsybovsky</surname><given-names>Y</given-names></name><name><surname>Stephens</surname><given-names>T</given-names></name><name><surname>Vaile</surname><given-names>JR</given-names></name><name><surname>Lederhofer</surname><given-names>J</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Fisher</surname><given-names>BE</given-names></name><name><surname>Yassine</surname><given-names>HM</given-names></name><name><surname>Andrews</surname><given-names>SF</given-names></name><name><surname>Crank</surname><given-names>MC</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Kanekiyo</surname><given-names>M</given-names></name></person-group><article-title>Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>791</fpage><?supplied-pmid 32034141?><pub-id pub-id-type="pmid">32034141</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broecker</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>STH</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Simon</surname><given-names>V</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Immunodominance of antigenic site B in the hemagglutinin of the current H3N2 influenza virus in humans and mice</article-title><source>J Virol</source><year>2018</year><volume>92</volume><fpage>e01100-18</fpage><?supplied-pmid 30045991?><pub-id pub-id-type="pmid">30045991</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>HH</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Assarsson</surname><given-names>E</given-names></name><name><surname>Mbawuike</surname><given-names>I</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><article-title>Ab and T cell epitopes of influenza A virus, knowledge and opportunities</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>246</fpage><lpage>251</lpage><?supplied-pmid 17200302?><pub-id pub-id-type="pmid">17200302</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caton</surname><given-names>AJ</given-names></name><name><surname>Brownlee</surname><given-names>GG</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Gerhard</surname><given-names>W</given-names></name></person-group><article-title>The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)</article-title><source>Cell</source><year>1982</year><volume>31</volume><fpage>417</fpage><lpage>427</lpage><?supplied-pmid 6186384?><pub-id pub-id-type="pmid">6186384</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Wohlbold</surname><given-names>TJ</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Neu</surname><given-names>KE</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Rojas</surname><given-names>KT</given-names></name><name><surname>Kirkpatrick</surname><given-names>E</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Palm</surname><given-names>AE</given-names></name><name><surname>Stamper</surname><given-names>CT</given-names></name><name><surname>Lan</surname><given-names>LY</given-names></name><name><surname>Topham</surname><given-names>DJ</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Eichelberger</surname><given-names>MC</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><article-title>Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies</article-title><source>Cell</source><year>2018</year><volume>173</volume><issue>417&#x02013;429</issue><fpage>e410</fpage></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Universal flu vaccine is &#x02018;an alchemist&#x02019;s dream&#x02019;</article-title><source>Science</source><year>2018</year><volume>362</volume><fpage>1094</fpage><?supplied-pmid 30523090?><pub-id pub-id-type="pmid">30523090</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>BE</given-names></name><name><surname>Bates</surname><given-names>JT</given-names></name><name><surname>Loomis</surname><given-names>RJ</given-names></name><name><surname>Baneyx</surname><given-names>G</given-names></name><name><surname>Carrico</surname><given-names>C</given-names></name><name><surname>Jardine</surname><given-names>JG</given-names></name><name><surname>Rupert</surname><given-names>P</given-names></name><name><surname>Correnti</surname><given-names>C</given-names></name><name><surname>Kalyuzhniy</surname><given-names>O</given-names></name><name><surname>Vittal</surname><given-names>V</given-names></name><name><surname>Connell</surname><given-names>MJ</given-names></name><name><surname>Stevens</surname><given-names>E</given-names></name><name><surname>Schroeter</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Macpherson</surname><given-names>S</given-names></name><name><surname>Serra</surname><given-names>AM</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Klevit</surname><given-names>RE</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Wyatt</surname><given-names>RT</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Johnson</surname><given-names>PR</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name></person-group><article-title>Proof of principle for epitope-focused vaccine design</article-title><source>Nature</source><year>2014</year><volume>507</volume><fpage>201</fpage><lpage>206</lpage><?supplied-pmid 24499818?><pub-id pub-id-type="pmid">24499818</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Voss</surname><given-names>J</given-names></name><name><surname>Gamblin</surname><given-names>SJ</given-names></name><name><surname>Codoni</surname><given-names>G</given-names></name><name><surname>Macagno</surname><given-names>A</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Vachieri</surname><given-names>SG</given-names></name><name><surname>Pinna</surname><given-names>D</given-names></name><name><surname>Minola</surname><given-names>A</given-names></name><name><surname>Vanzetta</surname><given-names>F</given-names></name><name><surname>Silacci</surname><given-names>C</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>BM</given-names></name><name><surname>Agatic</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Giacchetto-Sasselli</surname><given-names>I</given-names></name><name><surname>Calder</surname><given-names>L</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Haire</surname><given-names>LF</given-names></name><name><surname>Temperton</surname><given-names>N</given-names></name><name><surname>Langedijk</surname><given-names>JP</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><article-title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>850</fpage><lpage>856</lpage><?supplied-pmid 21798894?><pub-id pub-id-type="pmid">21798894</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Filette</surname><given-names>M</given-names></name><name><surname>Martens</surname><given-names>W</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Deroo</surname><given-names>T</given-names></name><name><surname>Vervalle</surname><given-names>F</given-names></name><name><surname>Bentahir</surname><given-names>M</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>An influenza A vaccine based on tetrameric ectodomain of matrix protein 2</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>11382</fpage><lpage>11387</lpage><?supplied-pmid 18252707?><pub-id pub-id-type="pmid">18252707</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>JC</given-names></name><name><surname>Beyer</surname><given-names>WE</given-names></name><name><surname>Palache</surname><given-names>AM</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly</article-title><source>J Med Virol</source><year>2000</year><volume>61</volume><fpage>94</fpage><lpage>99</lpage><?supplied-pmid 10745239?><pub-id pub-id-type="pmid">10745239</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>BZ</given-names></name></person-group><article-title>A perspective on nanoparticle universal influenza vaccines</article-title><source>ACS Infect Dis</source><year>2018</year><volume>4</volume><fpage>1656</fpage><lpage>1665</lpage><?supplied-pmid 30394725?><pub-id pub-id-type="pmid">30394725</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>KJ</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>M2e-based universal influenza A vaccines</article-title><source>Vaccin Basel</source><year>2015</year><volume>3</volume><fpage>105</fpage><lpage>136</lpage></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiLillo</surname><given-names>DJ</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><article-title>Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo</article-title><source>Nat Med</source><year>2014</year><volume>20</volume><fpage>143</fpage><lpage>151</lpage><?supplied-pmid 24412922?><pub-id pub-id-type="pmid">24412922</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>TM</given-names></name><name><surname>Hashem</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Van Domselaar</surname><given-names>G</given-names></name><name><surname>Larocque</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Cyr</surname><given-names>T</given-names></name><name><surname>Farnsworth</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Hurt</surname><given-names>AC</given-names></name><name><surname>Brown</surname><given-names>EG</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Universal anti-neuraminidase antibody inhibiting all influenza A subtypes</article-title><source>Antivir Res</source><year>2013</year><volume>100</volume><fpage>567</fpage><lpage>574</lpage><?supplied-pmid 24091204?><pub-id pub-id-type="pmid">24091204</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyfus</surname><given-names>C</given-names></name><name><surname>Laursen</surname><given-names>NS</given-names></name><name><surname>Kwaks</surname><given-names>T</given-names></name><name><surname>Zuijdgeest</surname><given-names>D</given-names></name><name><surname>Khayat</surname><given-names>R</given-names></name><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Metlagel</surname><given-names>Z</given-names></name><name><surname>Bujny</surname><given-names>MV</given-names></name><name><surname>Jongeneelen</surname><given-names>M</given-names></name><name><surname>van der Vlugt</surname><given-names>R</given-names></name><name><surname>Lamrani</surname><given-names>M</given-names></name><name><surname>Korse</surname><given-names>HJ</given-names></name><name><surname>Geelen</surname><given-names>E</given-names></name><name><surname>Sahin</surname><given-names>O</given-names></name><name><surname>Sieuwerts</surname><given-names>M</given-names></name><name><surname>Brakenhoff</surname><given-names>JP</given-names></name><name><surname>Vogels</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>OT</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Koudstaal</surname><given-names>W</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Friesen</surname><given-names>RH</given-names></name></person-group><article-title>Highly conserved protective epitopes on influenza B viruses</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>1343</fpage><lpage>1348</lpage><?supplied-pmid 22878502?><pub-id pub-id-type="pmid">22878502</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Cui</surname><given-names>Q</given-names></name><name><surname>Rong</surname><given-names>L</given-names></name></person-group><article-title>Competitive cooperation of hemagglutinin and neuraminidase during influenza A virus entry</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>458</fpage></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggink</surname><given-names>D</given-names></name><name><surname>Goff</surname><given-names>PH</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>699</fpage><lpage>704</lpage><?supplied-pmid 24155380?><pub-id pub-id-type="pmid">24155380</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Bhabha</surname><given-names>G</given-names></name><name><surname>Elsliger</surname><given-names>MA</given-names></name><name><surname>Friesen</surname><given-names>RH</given-names></name><name><surname>Jongeneelen</surname><given-names>M</given-names></name><name><surname>Throsby</surname><given-names>M</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><article-title>Antibody recognition of a highly conserved influenza virus epitope</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>246</fpage><lpage>251</lpage><?supplied-pmid 19251591?><pub-id pub-id-type="pmid">19251591</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Friesen</surname><given-names>RH</given-names></name><name><surname>Bhabha</surname><given-names>G</given-names></name><name><surname>Kwaks</surname><given-names>T</given-names></name><name><surname>Jongeneelen</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Ophorst</surname><given-names>C</given-names></name><name><surname>Cox</surname><given-names>F</given-names></name><name><surname>Korse</surname><given-names>HJ</given-names></name><name><surname>Brandenburg</surname><given-names>B</given-names></name><name><surname>Vogels</surname><given-names>R</given-names></name><name><surname>Brakenhoff</surname><given-names>JP</given-names></name><name><surname>Kompier</surname><given-names>R</given-names></name><name><surname>Koldijk</surname><given-names>MH</given-names></name><name><surname>Cornelissen</surname><given-names>LA</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Koudstaal</surname><given-names>W</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name></person-group><article-title>A highly conserved neutralizing epitope on group 2 influenza A viruses</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>843</fpage><lpage>850</lpage><?supplied-pmid 21737702?><pub-id pub-id-type="pmid">21737702</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Kashyap</surname><given-names>AK</given-names></name><name><surname>Steel</surname><given-names>J</given-names></name><name><surname>Rubrum</surname><given-names>A</given-names></name><name><surname>Bhabha</surname><given-names>G</given-names></name><name><surname>Khayat</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Dillon</surname><given-names>MA</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>RE</given-names></name><name><surname>Faynboym</surname><given-names>AM</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Horowitz</surname><given-names>L</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Bhatt</surname><given-names>RR</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><article-title>Cross-neutralization of influenza A viruses mediated by a single antibody loop</article-title><source>Nature</source><year>2012</year><volume>489</volume><fpage>526</fpage><lpage>532</lpage><?supplied-pmid 22982990?><pub-id pub-id-type="pmid">22982990</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliasson</surname><given-names>DG</given-names></name><name><surname>El Bakkouri</surname><given-names>K</given-names></name><name><surname>Schon</surname><given-names>K</given-names></name><name><surname>Ramne</surname><given-names>A</given-names></name><name><surname>Festjens</surname><given-names>E</given-names></name><name><surname>Lowenadler</surname><given-names>B</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Lycke</surname><given-names>N</given-names></name></person-group><article-title>CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>1243</fpage><lpage>1252</lpage><?supplied-pmid 18243429?><pub-id pub-id-type="pmid">18243429</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>SL</given-names></name></person-group><article-title>Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature</article-title><source>J Infect Dis</source><year>2006</year><volume>193</volume><fpage>49</fpage><lpage>53</lpage><?supplied-pmid 16323131?><pub-id pub-id-type="pmid">16323131</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermler</surname><given-names>ME</given-names></name><name><surname>Kirkpatrick</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Chromikova</surname><given-names>V</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model</article-title><source>J Virol</source><year>2017</year><volume>91</volume><fpage>e00286-17</fpage><?supplied-pmid 28356526?><pub-id pub-id-type="pmid">28356526</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farahmand</surname><given-names>B</given-names></name><name><surname>Taheri</surname><given-names>N</given-names></name><name><surname>Shokouhi</surname><given-names>H</given-names></name><name><surname>Soleimanjahi</surname><given-names>H</given-names></name><name><surname>Fotouhi</surname><given-names>F</given-names></name></person-group><article-title>Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation</article-title><source>Virus Genes</source><year>2019</year><volume>55</volume><fpage>22</fpage><lpage>32</lpage><?supplied-pmid 30382564?><pub-id pub-id-type="pmid">30382564</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florek</surname><given-names>NW</given-names></name><name><surname>Weinfurter</surname><given-names>JT</given-names></name><name><surname>Jegaskanda</surname><given-names>S</given-names></name><name><surname>Brewoo</surname><given-names>JN</given-names></name><name><surname>Powell</surname><given-names>TD</given-names></name><name><surname>Young</surname><given-names>GR</given-names></name><name><surname>Das</surname><given-names>SC</given-names></name><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Broman</surname><given-names>KW</given-names></name><name><surname>Hungnes</surname><given-names>O</given-names></name><name><surname>Dudman</surname><given-names>SG</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Stinchcomb</surname><given-names>DT</given-names></name><name><surname>Osorio</surname><given-names>JE</given-names></name><name><surname>Friedrich</surname><given-names>TC</given-names></name></person-group><article-title>Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>13418</fpage><lpage>13428</lpage><?supplied-pmid 25210172?><pub-id pub-id-type="pmid">25210172</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerdil</surname><given-names>C</given-names></name></person-group><article-title>The annual production cycle for influenza vaccine</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>1776</fpage><lpage>1779</lpage><?supplied-pmid 12686093?><pub-id pub-id-type="pmid">12686093</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gras</surname><given-names>S</given-names></name><name><surname>Kedzierski</surname><given-names>L</given-names></name><name><surname>Valkenburg</surname><given-names>SA</given-names></name><name><surname>Laurie</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Denholm</surname><given-names>JT</given-names></name><name><surname>Richards</surname><given-names>MJ</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name><name><surname>Turner</surname><given-names>SJ</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name></person-group><article-title>Cross-reactive CD8&#x02009;+&#x02009;T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>12599</fpage><lpage>12604</lpage><?supplied-pmid 20616031?><pub-id pub-id-type="pmid">20616031</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grayson</surname><given-names>KJ</given-names></name><name><surname>Anderson</surname><given-names>JLR</given-names></name></person-group><article-title>Designed for life: biocompatible de novo designed proteins and components</article-title><source>J R Soc Interface</source><year>2018</year><volume>15</volume><fpage>20180472</fpage><?supplied-pmid 30158186?><pub-id pub-id-type="pmid">30158186</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Kotturi</surname><given-names>MF</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Oseroff</surname><given-names>C</given-names></name><name><surname>Vaughan</surname><given-names>K</given-names></name><name><surname>Salimi</surname><given-names>N</given-names></name><name><surname>Vita</surname><given-names>R</given-names></name><name><surname>Ponomarenko</surname><given-names>J</given-names></name><name><surname>Scheuermann</surname><given-names>RH</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name></person-group><article-title>Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>20365</fpage><lpage>20370</lpage><?supplied-pmid 19918065?><pub-id pub-id-type="pmid">19918065</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Pica</surname><given-names>N</given-names></name><name><surname>Eggink</surname><given-names>D</given-names></name><name><surname>Maamary</surname><given-names>J</given-names></name><name><surname>Margine</surname><given-names>I</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>5774</fpage><lpage>5781</lpage><?supplied-pmid 22398287?><pub-id pub-id-type="pmid">22398287</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayward</surname><given-names>AC</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Goonetilleke</surname><given-names>N</given-names></name><name><surname>Fragaszy</surname><given-names>EB</given-names></name><name><surname>Bermingham</surname><given-names>A</given-names></name><name><surname>Copas</surname><given-names>A</given-names></name><name><surname>Dukes</surname><given-names>O</given-names></name><name><surname>Millett</surname><given-names>ER</given-names></name><name><surname>Nazareth</surname><given-names>I</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>JS</given-names></name><name><surname>Watson</surname><given-names>JM</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>AM</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name></person-group><article-title>Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study</article-title><source>Am J Respir Crit Care Med</source><year>2015</year><volume>191</volume><fpage>1422</fpage><lpage>1431</lpage><?supplied-pmid 25844934?><pub-id pub-id-type="pmid">25844934</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Mullarkey</surname><given-names>CE</given-names></name><name><surname>Duty</surname><given-names>JA</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>MS</given-names></name></person-group><article-title>Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones</article-title><source>J Virol</source><year>2015</year><volume>89</volume><fpage>3610</fpage><lpage>3618</lpage><?supplied-pmid 25589655?><pub-id pub-id-type="pmid">25589655</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaton</surname><given-names>NS</given-names></name><name><surname>Sachs</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>20248</fpage><lpage>20253</lpage><?supplied-pmid 24277853?><pub-id pub-id-type="pmid">24277853</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Palm</surname><given-names>AE</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><article-title>From original antigenic sin to the universal influenza virus vaccine</article-title><source>Trends Immunol</source><year>2018</year><volume>39</volume><fpage>70</fpage><lpage>79</lpage><?supplied-pmid 28867526?><pub-id pub-id-type="pmid">28867526</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Owino</surname><given-names>SO</given-names></name><name><surname>Crevar</surname><given-names>CJ</given-names></name><name><surname>Carter</surname><given-names>DM</given-names></name><name><surname>Ross</surname><given-names>TM</given-names></name></person-group><article-title>N-linked glycans and K147 residue on hemagglutinin synergize to elicit broadly-reactive H1N1 influenza antibodies</article-title><source>J Virol</source><year>2019</year><pub-id pub-id-type="doi">10.1128/JVI.01432-19</pub-id><?supplied-pmid 31597766?><pub-id pub-id-type="pmid">31597766</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Impagliazzo</surname><given-names>A</given-names></name><name><surname>Milder</surname><given-names>F</given-names></name><name><surname>Kuipers</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>MV</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hoffman</surname><given-names>RM</given-names></name><name><surname>van Meersbergen</surname><given-names>R</given-names></name><name><surname>Huizingh</surname><given-names>J</given-names></name><name><surname>Wanningen</surname><given-names>P</given-names></name><name><surname>Verspuij</surname><given-names>J</given-names></name><name><surname>de Man</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Apetri</surname><given-names>A</given-names></name><name><surname>Kukrer</surname><given-names>B</given-names></name><name><surname>Sneekes-Vriese</surname><given-names>E</given-names></name><name><surname>Tomkiewicz</surname><given-names>D</given-names></name><name><surname>Laursen</surname><given-names>NS</given-names></name><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Zakrzewska</surname><given-names>A</given-names></name><name><surname>Dekking</surname><given-names>L</given-names></name><name><surname>Tolboom</surname><given-names>J</given-names></name><name><surname>Tettero</surname><given-names>L</given-names></name><name><surname>van Meerten</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Koudstaal</surname><given-names>W</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Meijberg</surname><given-names>W</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Radosevic</surname><given-names>K</given-names></name></person-group><article-title>A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen</article-title><source>Science</source><year>2015</year><volume>349</volume><fpage>1301</fpage><lpage>1306</lpage><?supplied-pmid 26303961?><pub-id pub-id-type="pmid">26303961</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S</given-names></name><name><surname>Job</surname><given-names>ER</given-names></name><name><surname>Kramski</surname><given-names>M</given-names></name><name><surname>Laurie</surname><given-names>K</given-names></name><name><surname>Isitman</surname><given-names>G</given-names></name><name><surname>de Rose</surname><given-names>R</given-names></name><name><surname>Winnall</surname><given-names>WR</given-names></name><name><surname>Stratov</surname><given-names>I</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Reading</surname><given-names>PC</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies</article-title><source>J Immunol</source><year>2013</year><volume>190</volume><fpage>1837</fpage><lpage>1848</lpage><?supplied-pmid 23319732?><pub-id pub-id-type="pmid">23319732</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S</given-names></name><name><surname>Weinfurter</surname><given-names>JT</given-names></name><name><surname>Friedrich</surname><given-names>TC</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>5512</fpage><lpage>5522</lpage><?supplied-pmid 23468501?><pub-id pub-id-type="pmid">23468501</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S</given-names></name><name><surname>Reading</surname><given-names>PC</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine</article-title><source>J Immunol</source><year>2014</year><volume>193</volume><fpage>469</fpage><lpage>475</lpage><?supplied-pmid 24994909?><pub-id pub-id-type="pmid">24994909</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S</given-names></name><name><surname>Andrews</surname><given-names>SF</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name></person-group><article-title>Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines</article-title><source>JCI Insight</source><year>2019</year><volume>4</volume><fpage>e129035</fpage></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanekiyo</surname><given-names>M</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Gillespie</surname><given-names>RA</given-names></name><name><surname>Gallagher</surname><given-names>JR</given-names></name><name><surname>Andrews</surname><given-names>SF</given-names></name><name><surname>Yassine</surname><given-names>HM</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name><name><surname>Fisher</surname><given-names>BE</given-names></name><name><surname>Ambrozak</surname><given-names>DR</given-names></name><name><surname>Creanga</surname><given-names>A</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Boyoglu-Barnum</surname><given-names>S</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Tsybovsky</surname><given-names>Y</given-names></name><name><surname>Prabhakaran</surname><given-names>MS</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>W-P</given-names></name><name><surname>Baxa</surname><given-names>U</given-names></name><name><surname>Zephir</surname><given-names>KL</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Harris</surname><given-names>AK</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>362</fpage><lpage>372</lpage><?supplied-pmid 30742080?><pub-id pub-id-type="pmid">30742080</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Song</surname><given-names>JM</given-names></name><name><surname>Eunju</surname><given-names>O</given-names></name><name><surname>Kwon</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus</article-title><source>Mol Ther</source><year>2013</year><volume>21</volume><fpage>485</fpage><lpage>492</lpage><?supplied-pmid 23247101?><pub-id pub-id-type="pmid">23247101</pub-id></element-citation></ref><ref id="CR52"><mixed-citation publication-type="other">Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nussing S, Fox A, Chung AW, Laurie KL, Hurt AC, Rockman S, Lappas M, Loudovaris T, Mannering SI, Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K (2018) Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci Transl Med 10:eaan8405</mixed-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsakos</surname><given-names>M</given-names></name><name><surname>Illing</surname><given-names>PT</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Mifsud</surname><given-names>NA</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Rizzetto</surname><given-names>S</given-names></name><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Clemens</surname><given-names>EB</given-names></name><name><surname>Sant</surname><given-names>S</given-names></name><name><surname>Chua</surname><given-names>BY</given-names></name><name><surname>Wong</surname><given-names>CY</given-names></name><name><surname>Allen</surname><given-names>EK</given-names></name><name><surname>Teng</surname><given-names>D</given-names></name><name><surname>Dash</surname><given-names>P</given-names></name><name><surname>Boyd</surname><given-names>DF</given-names></name><name><surname>Grzelak</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Hurt</surname><given-names>AC</given-names></name><name><surname>Barr</surname><given-names>I</given-names></name><name><surname>Rockman</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>DC</given-names></name><name><surname>Kotsimbos</surname><given-names>TC</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Westall</surname><given-names>GP</given-names></name><name><surname>Loudovaris</surname><given-names>T</given-names></name><name><surname>Mannering</surname><given-names>SI</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Wakim</surname><given-names>LM</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Vijaykrishna</surname><given-names>D</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name><name><surname>Purcell</surname><given-names>AW</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name></person-group><article-title>Human CD8(+) T cell cross-reactivity across influenza A, B and C viruses</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>613</fpage><lpage>625</lpage><?supplied-pmid 30778243?><pub-id pub-id-type="pmid">30778243</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>The human antibody response to influenza A virus infection and vaccination</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><fpage>383</fpage><lpage>397</lpage><?supplied-pmid 30837674?><pub-id pub-id-type="pmid">30837674</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Advances in the development of influenza virus vaccines</article-title><source>Nat Rev Drug Discov</source><year>2015</year><volume>14</volume><fpage>167</fpage><lpage>182</lpage><?supplied-pmid 25722244?><pub-id pub-id-type="pmid">25722244</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain</article-title><source>J Infect Dis</source><year>2019</year><volume>219</volume><fpage>S62</fpage><lpage>S67</lpage><?supplied-pmid 30715353?><pub-id pub-id-type="pmid">30715353</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Pica</surname><given-names>N</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Margine</surname><given-names>I</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>6542</fpage><lpage>6550</lpage><?supplied-pmid 23576508?><pub-id pub-id-type="pmid">23576508</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>GJD</given-names></name><name><surname>Fouchier</surname><given-names>RAM</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>ML</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name></person-group><article-title>Influenza</article-title><source>Nat Rev Dis Primers</source><year>2018</year><volume>4</volume><fpage>3</fpage><?supplied-pmid 29955068?><pub-id pub-id-type="pmid">29955068</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>JC</given-names></name><name><surname>Tsibane</surname><given-names>T</given-names></name><name><surname>Tumpey</surname><given-names>TM</given-names></name><name><surname>Huffman</surname><given-names>CJ</given-names></name><name><surname>Albrecht</surname><given-names>R</given-names></name><name><surname>Blum</surname><given-names>DL</given-names></name><name><surname>Ramos</surname><given-names>I</given-names></name><name><surname>Fernandez-Sesma</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>KM</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Basler</surname><given-names>CF</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>6334</fpage><lpage>6340</lpage><?supplied-pmid 22457520?><pub-id pub-id-type="pmid">22457520</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Carey</surname><given-names>JB</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Spencer</surname><given-names>AJ</given-names></name><name><surname>van Laarhoven</surname><given-names>A</given-names></name><name><surname>Mullarkey</surname><given-names>CE</given-names></name><name><surname>Vrdoljak</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>AC</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1</article-title><source>Sci Rep</source><year>2013</year><volume>3</volume><fpage>1443</fpage><?supplied-pmid 23485942?><pub-id pub-id-type="pmid">23485942</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Takada</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><article-title>Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><fpage>17040</fpage><lpage>17045</lpage><?supplied-pmid 23027945?><pub-id pub-id-type="pmid">23027945</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Ohshima</surname><given-names>N</given-names></name><name><surname>Stanfield</surname><given-names>RL</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Iba</surname><given-names>Y</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Kurosawa</surname><given-names>Y</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><article-title>Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>3614</fpage><?supplied-pmid 24717798?><pub-id pub-id-type="pmid">24717798</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GM</given-names></name><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>McCausland</surname><given-names>M</given-names></name><name><surname>Andrews</surname><given-names>SF</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Edupuganti</surname><given-names>S</given-names></name><name><surname>Mulligan</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>SR</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><fpage>9047</fpage><lpage>9052</lpage><?supplied-pmid 22615367?><pub-id pub-id-type="pmid">22615367</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lillie</surname><given-names>PJ</given-names></name><name><surname>Berthoud</surname><given-names>TK</given-names></name><name><surname>Powell</surname><given-names>TJ</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Mullarkey</surname><given-names>C</given-names></name><name><surname>Spencer</surname><given-names>AJ</given-names></name><name><surname>Hamill</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Blais</surname><given-names>ME</given-names></name><name><surname>Duncan</surname><given-names>CJ</given-names></name><name><surname>Sheehy</surname><given-names>SH</given-names></name><name><surname>Havelock</surname><given-names>T</given-names></name><name><surname>Faust</surname><given-names>SN</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Gilbert</surname><given-names>A</given-names></name><name><surname>Oxford</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP&#x02009;+&#x02009;M1, in humans</article-title><source>Clin Infect Dis</source><year>2012</year><volume>55</volume><fpage>19</fpage><lpage>25</lpage><?supplied-pmid 22441650?><pub-id pub-id-type="pmid">22441650</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Chong</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>SC</given-names></name></person-group><article-title>Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e39075</fpage><?supplied-pmid 22720032?><pub-id pub-id-type="pmid">22720032</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group><article-title>N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication</article-title><source>FEMS Immunol Med Microbiol</source><year>2003</year><volume>35</volume><fpage>141</fpage><lpage>146</lpage><?supplied-pmid 12628550?><pub-id pub-id-type="pmid">12628550</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>STH</given-names></name><name><surname>Behzadi</surname><given-names>MA</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Freyn</surname><given-names>AW</given-names></name><name><surname>Liu</surname><given-names>WC</given-names></name><name><surname>Broecker</surname><given-names>F</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>Bouvier</surname><given-names>NM</given-names></name><name><surname>Simon</surname><given-names>V</given-names></name><name><surname>Nachbagauer</surname><given-names>R</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><fpage>4992</fpage><lpage>4996</lpage><?supplied-pmid 30188868?><pub-id pub-id-type="pmid">30188868</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Welsh</surname><given-names>JP</given-names></name><name><surname>Swartz</surname><given-names>JR</given-names></name></person-group><article-title>Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>125</fpage><lpage>130</lpage><?supplied-pmid 24344259?><pub-id pub-id-type="pmid">24344259</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallajosyula</surname><given-names>VV</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name><name><surname>Ferrara</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Callahan</surname><given-names>C</given-names></name><name><surname>Heidecker</surname><given-names>GJ</given-names></name><name><surname>Sarma</surname><given-names>SP</given-names></name><name><surname>Flynn</surname><given-names>JA</given-names></name><name><surname>Temperton</surname><given-names>NJ</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Varadarajan</surname><given-names>R</given-names></name></person-group><article-title>Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>E2514</fpage><lpage>E2523</lpage><?supplied-pmid 24927560?><pub-id pub-id-type="pmid">24927560</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandala</surname><given-names>VS</given-names></name><name><surname>Liao</surname><given-names>SY</given-names></name><name><surname>Gelenter</surname><given-names>MD</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name></person-group><article-title>The Transmembrane conformation of the influenza B virus M2 protein in lipid bilayers</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>3725</fpage><?supplied-pmid 30842530?><pub-id pub-id-type="pmid">30842530</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margine</surname><given-names>I</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Heaton</surname><given-names>NS</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>SA</given-names></name><name><surname>Runstadler</surname><given-names>JA</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>10435</fpage><lpage>10446</lpage><?supplied-pmid 23903831?><pub-id pub-id-type="pmid">23903831</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Gotch</surname><given-names>FM</given-names></name><name><surname>Noble</surname><given-names>GR</given-names></name><name><surname>Beare</surname><given-names>PA</given-names></name></person-group><article-title>Cytotoxic T-cell immunity to influenza</article-title><source>N Engl J Med</source><year>1983</year><volume>309</volume><fpage>13</fpage><lpage>17</lpage><?supplied-pmid 6602294?><pub-id pub-id-type="pmid">6602294</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memoli</surname><given-names>MJ</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Walters</surname><given-names>KA</given-names></name><name><surname>Czajkowski</surname><given-names>L</given-names></name><name><surname>Reed</surname><given-names>S</given-names></name><name><surname>Athota</surname><given-names>R</given-names></name><name><surname>Rosas</surname><given-names>LA</given-names></name><name><surname>Cervantes-Medina</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Morens</surname><given-names>DM</given-names></name><name><surname>Kash</surname><given-names>JC</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name></person-group><article-title>Influenza A reinfection in sequential human challenge: implications for protective immunity and &#x0201c;universal&#x0201d; vaccine development</article-title><source>Clin Infect Dis</source><year>2019</year><pub-id pub-id-type="doi">10.1093/cid/ciz281</pub-id><?supplied-pmid 30770534?><pub-id pub-id-type="pmid">30770534</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesin</surname><given-names>L</given-names></name><name><surname>Schiepers</surname><given-names>A</given-names></name><name><surname>Ersching</surname><given-names>J</given-names></name><name><surname>Barbulescu</surname><given-names>A</given-names></name><name><surname>Cavazzoni</surname><given-names>CB</given-names></name><name><surname>Angelini</surname><given-names>A</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Victora</surname><given-names>GD</given-names></name></person-group><article-title>Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>92</fpage><lpage>106.e11</lpage><?supplied-pmid 31866068?><pub-id pub-id-type="pmid">31866068</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mezhenskaya</surname><given-names>D</given-names></name><name><surname>Isakova-Sivak</surname><given-names>I</given-names></name><name><surname>Rudenko</surname><given-names>L</given-names></name></person-group><article-title>M2e-based universal influenza vaccines: a historical overview and new approaches to development</article-title><source>J Biomed Sci</source><year>2019</year><volume>26</volume><fpage>76</fpage><?supplied-pmid 31629405?><pub-id pub-id-type="pmid">31629405</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MS</given-names></name><name><surname>Tsibane</surname><given-names>T</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Rahmat</surname><given-names>S</given-names></name><name><surname>Basler</surname><given-names>CF</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans</article-title><source>J Infect Dis</source><year>2013</year><volume>207</volume><fpage>98</fpage><lpage>105</lpage><?supplied-pmid 23087428?><pub-id pub-id-type="pmid">23087428</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monto</surname><given-names>AS</given-names></name><name><surname>Kendal</surname><given-names>AP</given-names></name></person-group><article-title>Effect of neuraminidase antibody on Hong Kong influenza</article-title><source>Lancet</source><year>1973</year><volume>1</volume><fpage>623</fpage><lpage>625</lpage><?supplied-pmid 4121842?><pub-id pub-id-type="pmid">4121842</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>BR</given-names></name><name><surname>Kasel</surname><given-names>JA</given-names></name><name><surname>Chanock</surname><given-names>RM</given-names></name></person-group><article-title>Association of serum anti-neuraminidase antibody with resistance to influenza in man</article-title><source>N Engl J Med</source><year>1972</year><volume>286</volume><fpage>1329</fpage><lpage>1332</lpage><?supplied-pmid 5027388?><pub-id pub-id-type="pmid">5027388</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachbagauer</surname><given-names>R</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>Universal influenza virus vaccines and therapeutic antibodies</article-title><source>Clin Microbiol Infect</source><year>2017</year><volume>23</volume><fpage>222</fpage><lpage>228</lpage><?supplied-pmid 28216325?><pub-id pub-id-type="pmid">28216325</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neirynck</surname><given-names>S</given-names></name><name><surname>Deroo</surname><given-names>T</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Vanlandschoot</surname><given-names>P</given-names></name><name><surname>Jou</surname><given-names>WM</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name></person-group><article-title>A universal influenza A vaccine based on the extracellular domain of the M2 protein</article-title><source>Nat Med</source><year>1999</year><volume>5</volume><fpage>1157</fpage><lpage>1163</lpage><?supplied-pmid 10502819?><pub-id pub-id-type="pmid">10502819</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Isegawa</surname><given-names>Y</given-names></name><name><surname>Sasao</surname><given-names>F</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name></person-group><article-title>A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains</article-title><source>J Virol</source><year>1993</year><volume>67</volume><fpage>2552</fpage><lpage>2558</lpage><?supplied-pmid 7682624?><pub-id pub-id-type="pmid">7682624</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pica</surname><given-names>N</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Maamary</surname><given-names>J</given-names></name><name><surname>Eggink</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Krause</surname><given-names>JC</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Stein</surname><given-names>CR</given-names></name><name><surname>Banach</surname><given-names>D</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Belshe</surname><given-names>RB</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><fpage>2573</fpage><lpage>2578</lpage><?supplied-pmid 22308500?><pub-id pub-id-type="pmid">22308500</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Leung</surname><given-names>YHC</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name><name><surname>Perera</surname><given-names>P-Y</given-names></name><name><surname>Lichy</surname><given-names>JH</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Perera</surname><given-names>LP</given-names></name></person-group><article-title>Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice</article-title><source>J Immunol Baltim Md 1950</source><year>2009</year><volume>182</volume><fpage>3063</fpage><lpage>3071</lpage></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinones-Parra</surname><given-names>S</given-names></name><name><surname>Grant</surname><given-names>E</given-names></name><name><surname>Loh</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Campbell</surname><given-names>KA</given-names></name><name><surname>Tong</surname><given-names>SY</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name><name><surname>Vijaykrishna</surname><given-names>D</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name></person-group><article-title>Preexisting CD8&#x02009;+&#x02009;T-cell immunity to the H7N9 influenza A virus varies across ethnicities</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>1049</fpage><lpage>1054</lpage><?supplied-pmid 24395804?><pub-id pub-id-type="pmid">24395804</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedel</surname><given-names>T</given-names></name><name><surname>Ghasparian</surname><given-names>A</given-names></name><name><surname>Moehle</surname><given-names>K</given-names></name><name><surname>Rusert</surname><given-names>P</given-names></name><name><surname>Trkola</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>JA</given-names></name></person-group><article-title>Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design</article-title><source>ChemBioChem</source><year>2011</year><volume>12</volume><fpage>2829</fpage><lpage>2836</lpage><?supplied-pmid 22076829?><pub-id pub-id-type="pmid">22076829</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>JL</given-names></name><name><surname>Khakpour</surname><given-names>M</given-names></name><name><surname>Kilbourne</surname><given-names>ED</given-names></name></person-group><article-title>Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice</article-title><source>J Virol</source><year>1968</year><volume>2</volume><fpage>778</fpage><lpage>786</lpage><?supplied-pmid 5701819?><pub-id pub-id-type="pmid">5701819</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sesterhenn</surname><given-names>F</given-names></name><name><surname>Galloux</surname><given-names>M</given-names></name><name><surname>Vollers</surname><given-names>SS</given-names></name><name><surname>Csepregi</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Friedensohn</surname><given-names>S</given-names></name><name><surname>Gainza</surname><given-names>P</given-names></name><name><surname>Corth&#x000e9;sy</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Rosset</surname><given-names>S</given-names></name><name><surname>Rameix-Welti</surname><given-names>MA</given-names></name><name><surname>&#x000c9;l&#x000e9;ou&#x000eb;t</surname><given-names>JF</given-names></name><name><surname>Reddy</surname><given-names>ST</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Riffault</surname><given-names>S</given-names></name><name><surname>Correia</surname><given-names>BE</given-names></name></person-group><article-title>Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen</article-title><source>PLoS Biol</source><year>2019</year><volume>17</volume><fpage>e3000164</fpage><?supplied-pmid 30789898?><pub-id pub-id-type="pmid">30789898</pub-id></element-citation></ref><ref id="CR88"><mixed-citation publication-type="other">Sesterhenn F, Yang C, Bonet J, Cramer JT, Wen X, Wang Y, Chiang CI, Abriata LA, Kucharska I, Castoro G, Vollers SS, Galloux M, Dheilly E, Rosset S, Corth&#x000e9;sy P, Georgeon S, Villard M, Richard CA, Descamps D, Delgado T, Oricchio E, Rameix-Welti MA, M&#x000e1;s&#x000a0;V, Ervin S, El&#x000e9;ou&#x000eb;t JF, Riffault S, Bates JT, Julien JP, Li Y, Jardetzky T, Krey T, Correia BE (2020) De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science 368:eaay5051</mixed-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheikh</surname><given-names>QM</given-names></name><name><surname>Gatherer</surname><given-names>D</given-names></name><name><surname>Reche</surname><given-names>PA</given-names></name><name><surname>Flower</surname><given-names>DR</given-names></name></person-group><article-title>Towards the knowledge-based design of universal influenza epitope ensemble vaccines</article-title><source>Bioinform Oxf Engl</source><year>2016</year><volume>32</volume><fpage>3233</fpage><lpage>3239</lpage></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sridhar</surname><given-names>S</given-names></name><name><surname>Begom</surname><given-names>S</given-names></name><name><surname>Bermingham</surname><given-names>A</given-names></name><name><surname>Hoschler</surname><given-names>K</given-names></name><name><surname>Adamson</surname><given-names>W</given-names></name><name><surname>Carman</surname><given-names>W</given-names></name><name><surname>Bean</surname><given-names>T</given-names></name><name><surname>Barclay</surname><given-names>W</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Lalvani</surname><given-names>A</given-names></name></person-group><article-title>Cellular immune correlates of protection against symptomatic pandemic influenza</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>1305</fpage><lpage>1312</lpage><?supplied-pmid 24056771?><pub-id pub-id-type="pmid">24056771</pub-id></element-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadlbauer</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>JS</given-names></name><name><surname>Wohlbold</surname><given-names>TJ</given-names></name><name><surname>Schmitz</surname><given-names>AJ</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Nachbagauer</surname><given-names>R</given-names></name><name><surname>Mudd</surname><given-names>PA</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Ellebedy</surname><given-names>AH</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>Broadly protective human antibodies that target the active site of influenza virus neuraminidase</article-title><source>Science</source><year>2019</year><volume>366</volume><fpage>499</fpage><lpage>504</lpage><?supplied-pmid 31649200?><pub-id pub-id-type="pmid">31649200</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steel</surname><given-names>J</given-names></name><name><surname>Lowen</surname><given-names>AC</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Yondola</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Haye</surname><given-names>K</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Influenza virus vaccine based on the conserved hemagglutinin stalk domain</article-title><source>MBio</source><year>2010</year><volume>1</volume><fpage>e00018-10</fpage><?supplied-pmid 20689752?><pub-id pub-id-type="pmid">20689752</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>WC</given-names></name><name><surname>Perez</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Aird</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>LM</given-names></name><name><surname>Santelli</surname><given-names>E</given-names></name><name><surname>Stec</surname><given-names>B</given-names></name><name><surname>Cadwell</surname><given-names>G</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Yammanuru</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><name><surname>Bankston</surname><given-names>LA</given-names></name><name><surname>Donis</surname><given-names>RO</given-names></name><name><surname>Liddington</surname><given-names>RC</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name></person-group><article-title>Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses</article-title><source>Nat Struct Mol Biol</source><year>2009</year><volume>16</volume><fpage>265</fpage><lpage>273</lpage><?supplied-pmid 19234466?><pub-id pub-id-type="pmid">19234466</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Sheehan</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>WC</given-names></name><name><surname>Bankston</surname><given-names>LA</given-names></name><name><surname>Burchett</surname><given-names>SK</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Liddington</surname><given-names>RC</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name></person-group><article-title>Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies</article-title><source>Clin Infect Dis</source><year>2011</year><volume>52</volume><fpage>1003</fpage><lpage>1009</lpage><?supplied-pmid 21460314?><pub-id pub-id-type="pmid">21460314</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Kirkpatrick</surname><given-names>E</given-names></name><name><surname>Ermler</surname><given-names>M</given-names></name><name><surname>Nachbagauer</surname><given-names>R</given-names></name><name><surname>Broecker</surname><given-names>F</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Development of influenza B universal vaccine candidates using the &#x0201c;Mosaic&#x0201d; hemagglutinin approach</article-title><source>J Virol</source><year>2019</year><volume>93</volume><fpage>e00333-19</fpage><?supplied-pmid 30944178?><pub-id pub-id-type="pmid">30944178</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terajima</surname><given-names>M</given-names></name><name><surname>Cruz</surname><given-names>J</given-names></name><name><surname>Co</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kaur</surname><given-names>K</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name><name><surname>Ennis</surname><given-names>FA</given-names></name></person-group><article-title>Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies</article-title><source>J Virol</source><year>2011</year><volume>85</volume><fpage>13463</fpage><lpage>13467</lpage><?supplied-pmid 21994454?><pub-id pub-id-type="pmid">21994454</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobler</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>ML</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Effect of cytoplasmic tail truncations on the activity of the M(2) ion channel of influenza A virus</article-title><source>J Virol</source><year>1999</year><volume>73</volume><fpage>9695</fpage><lpage>9701</lpage><?supplied-pmid 10559278?><pub-id pub-id-type="pmid">10559278</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>JJ</given-names></name><name><surname>Tierney</surname><given-names>EL</given-names></name><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name></person-group><article-title>Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice</article-title><source>J Virol</source><year>1990</year><volume>64</volume><fpage>1375</fpage><lpage>1377</lpage><?supplied-pmid 2304147?><pub-id pub-id-type="pmid">2304147</pub-id></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turley</surname><given-names>CB</given-names></name><name><surname>Rupp</surname><given-names>RE</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>DN</given-names></name><name><surname>Wolfson</surname><given-names>J</given-names></name><name><surname>Tussey</surname><given-names>L</given-names></name><name><surname>Kavita</surname><given-names>U</given-names></name><name><surname>Stanberry</surname><given-names>L</given-names></name><name><surname>Shaw</surname><given-names>A</given-names></name></person-group><article-title>Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>5145</fpage><lpage>5152</lpage><?supplied-pmid 21624416?><pub-id pub-id-type="pmid">21624416</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valkenburg</surname><given-names>SA</given-names></name><name><surname>Li</surname><given-names>OTW</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Bull</surname><given-names>M</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Perera</surname><given-names>LP</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name></person-group><article-title>Protection by universal influenza vaccine is mediated by memory CD4 T cells</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>4198</fpage><lpage>4206</lpage><?supplied-pmid 29887326?><pub-id pub-id-type="pmid">29887326</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Couzens</surname><given-names>LK</given-names></name><name><surname>Rivers</surname><given-names>KH</given-names></name><name><surname>Easterbrook</surname><given-names>JD</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Rajabi</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Sultana</surname><given-names>I</given-names></name><name><surname>Wan</surname><given-names>XF</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Perez</surname><given-names>DR</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Eichelberger</surname><given-names>MC</given-names></name></person-group><article-title>Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>9290</fpage><lpage>9300</lpage><?supplied-pmid 23785204?><pub-id pub-id-type="pmid">23785204</pub-id></element-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Biochemistry. Catching a moving target</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>834</fpage><lpage>835</lpage><?supplied-pmid 21836007?><pub-id pub-id-type="pmid">21836007</pub-id></element-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Quinones-Parra</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Loh</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Inouye</surname><given-names>M</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>6833</fpage><?supplied-pmid 25967273?><pub-id pub-id-type="pmid">25967273</pub-id></element-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Sant</surname><given-names>S</given-names></name><name><surname>Quinones-Parra</surname><given-names>SM</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Rizzetto</surname><given-names>S</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Koutsakos</surname><given-names>M</given-names></name><name><surname>Clemens</surname><given-names>EB</given-names></name><name><surname>Loh</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Kedzierski</surname><given-names>L</given-names></name><name><surname>Kotsimbos</surname><given-names>T</given-names></name><name><surname>McCaw</surname><given-names>JM</given-names></name><name><surname>La Gruta</surname><given-names>NL</given-names></name><name><surname>Turner</surname><given-names>SJ</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name></person-group><article-title>Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>824</fpage><?supplied-pmid 29483513?><pub-id pub-id-type="pmid">29483513</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanitchang</surname><given-names>A</given-names></name><name><surname>Wongthida</surname><given-names>P</given-names></name><name><surname>Jongkaewwattana</surname><given-names>A</given-names></name></person-group><article-title>Influenza B virus M2 protein can functionally replace its influenza A virus counterpart in promoting virus replication</article-title><source>Virology</source><year>2016</year><volume>498</volume><fpage>99</fpage><lpage>108</lpage><?supplied-pmid 27567258?><pub-id pub-id-type="pmid">27567258</pub-id></element-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>KR</given-names></name><name><surname>Kuraoka</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Tonouchi</surname><given-names>K</given-names></name><name><surname>Caradonna</surname><given-names>TM</given-names></name><name><surname>Bajic</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>McGee</surname><given-names>CE</given-names></name><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Urick</surname><given-names>P</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><article-title>Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism</article-title><source>Cell</source><year>2019</year><volume>177</volume><issue>1124&#x02013;1135</issue><fpage>e1116</fpage></element-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidenbacher</surname><given-names>PA</given-names></name><name><surname>Kim</surname><given-names>PS</given-names></name></person-group><article-title>Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><fpage>9947</fpage><lpage>9952</lpage><?supplied-pmid 31028143?><pub-id pub-id-type="pmid">31028143</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>TM</given-names></name><name><surname>Li</surname><given-names>CKF</given-names></name><name><surname>Chui</surname><given-names>CSC</given-names></name><name><surname>Huang</surname><given-names>AKY</given-names></name><name><surname>Perkins</surname><given-names>M</given-names></name><name><surname>Liebner</surname><given-names>JC</given-names></name><name><surname>Lambkin-Williams</surname><given-names>R</given-names></name><name><surname>Gilbert</surname><given-names>A</given-names></name><name><surname>Oxford</surname><given-names>J</given-names></name><name><surname>Nicholas</surname><given-names>B</given-names></name><name><surname>Staples</surname><given-names>KJ</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Xu</surname><given-names>X-N</given-names></name></person-group><article-title>Preexisting influenza-specific CD4&#x02009;+&#x02009;T cells correlate with disease protection against influenza challenge in humans</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>274</fpage><lpage>280</lpage><?supplied-pmid 22286307?><pub-id pub-id-type="pmid">22286307</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>JR</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Reber</surname><given-names>A</given-names></name><name><surname>Kamal</surname><given-names>RP</given-names></name><name><surname>Music</surname><given-names>N</given-names></name><name><surname>Gansebom</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name><name><surname>Carney</surname><given-names>P</given-names></name><name><surname>Tzeng</surname><given-names>WP</given-names></name><name><surname>Stevens</surname><given-names>J</given-names></name><name><surname>York</surname><given-names>IA</given-names></name></person-group><article-title>An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo</article-title><source>Antivir Res</source><year>2016</year><volume>135</volume><fpage>48</fpage><lpage>55</lpage><?supplied-pmid 27713074?><pub-id pub-id-type="pmid">27713074</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlbold</surname><given-names>TJ</given-names></name><name><surname>Podolsky</surname><given-names>KA</given-names></name><name><surname>Chromikova</surname><given-names>V</given-names></name><name><surname>Kirkpatrick</surname><given-names>E</given-names></name><name><surname>Falconieri</surname><given-names>V</given-names></name><name><surname>Meade</surname><given-names>P</given-names></name><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>tenOever</surname><given-names>BR</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes</article-title><source>Nat Microbiol</source><year>2017</year><volume>2</volume><fpage>1415</fpage><lpage>1424</lpage><?supplied-pmid 28827718?><pub-id pub-id-type="pmid">28827718</pub-id></element-citation></ref><ref id="CR111"><mixed-citation publication-type="other">World Health Organization (WHO) (2018) 2018 Influenza (seasonal) fact sheet. WHO, Geneva, Switzerland. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs211/en/">http://www.who.int/mediacentre/factsheets/fs211/en/</ext-link>. Accessed 6 June 2020</mixed-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worobey</surname><given-names>M</given-names></name><name><surname>Plotkin</surname><given-names>S</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name></person-group><article-title>Influenza vaccines delivered in early childhood could turn antigenic sin into antigenic blessings</article-title><source>Cold Spring Harb Perspect Med</source><year>2020</year><pub-id pub-id-type="doi">10.1101/cshperspect.a038471</pub-id><?supplied-pmid 31964642?><pub-id pub-id-type="pmid">31964642</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Koutsonanos</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>GM</given-names></name><name><surname>Edupuganti</surname><given-names>S</given-names></name><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Morrissey</surname><given-names>M</given-names></name><name><surname>McCausland</surname><given-names>M</given-names></name><name><surname>Skountzou</surname><given-names>I</given-names></name><name><surname>Hornig</surname><given-names>M</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Razavi</surname><given-names>B</given-names></name><name><surname>Del Rio</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Kaur</surname><given-names>K</given-names></name><name><surname>Andrews</surname><given-names>S</given-names></name><name><surname>Amara</surname><given-names>RR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Das</surname><given-names>SR</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>CD</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name><name><surname>Mulligan</surname><given-names>MJ</given-names></name><name><surname>Compans</surname><given-names>R</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><article-title>Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection</article-title><source>J Exp Med</source><year>2011</year><volume>208</volume><fpage>181</fpage><lpage>193</lpage><?supplied-pmid 21220454?><pub-id pub-id-type="pmid">21220454</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group><article-title>&#x0201c;Breathing&#x0201d; hemagglutinin reveals cryptic epitopes for universal influenza vaccine design</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1086</fpage><lpage>1088</lpage><?supplied-pmid 31100263?><pub-id pub-id-type="pmid">31100263</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><article-title>Structural insights into the design of novel anti-influenza therapies</article-title><source>Nat Struct Mol Biol</source><year>2018</year><volume>25</volume><fpage>115</fpage><lpage>121</lpage><?supplied-pmid 29396418?><pub-id pub-id-type="pmid">29396418</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Protection against homo and hetero-subtypic in fluenza A virus by optimized M2e DNA vaccine</article-title><source>Emerg Microb Infect</source><year>2019</year><volume>8</volume><fpage>45</fpage><lpage>54</lpage></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yassine</surname><given-names>HM</given-names></name><name><surname>Boyington</surname><given-names>JC</given-names></name><name><surname>McTamney</surname><given-names>PM</given-names></name><name><surname>Wei</surname><given-names>CJ</given-names></name><name><surname>Kanekiyo</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>WP</given-names></name><name><surname>Gallagher</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>Moin</surname><given-names>SM</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>SS</given-names></name><name><surname>Harris</surname><given-names>AK</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>1065</fpage><lpage>1070</lpage><?supplied-pmid 26301691?><pub-id pub-id-type="pmid">26301691</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein</article-title><source>Proc Natl Acad Sci U S A</source><year>1989</year><volume>86</volume><fpage>1061</fpage><lpage>1065</lpage><?supplied-pmid 2915973?><pub-id pub-id-type="pmid">2915973</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbe</surname><given-names>K</given-names></name><name><surname>Moehle</surname><given-names>K</given-names></name><name><surname>Robinson</surname><given-names>JA</given-names></name></person-group><article-title>Protein epitope mimetics: from new antibiotics to supramolecular synthetic vaccines</article-title><source>Acc Chem Res</source><year>2017</year><volume>50</volume><fpage>1323</fpage><lpage>1331</lpage><?supplied-pmid 28570824?><pub-id pub-id-type="pmid">28570824</pub-id></element-citation></ref></ref-list></back></article>